CD8A and non-small cell lung carcinoma: Therefore, we use cutoff point value of PD-1+ IFN-γ+ cell percentages of CD8+ T cells in 30 patients with NSCLC to calculate PFS (time from the time starting anti–PD-1 therapy until disease progression or death from any cause, follow-up for 12 months).